| Nitazoxanide superiority to placebo to treat moderate COVID-19–A Pilot prove of concept randomized double-blind clinical trial. VF Blum, S Cimerman, JR Hunter, P Tierno, A Lacerda, A Soeiro, ... EClinicalMedicine 37, 2021 | 57 | 2021 |
| Is hepatitis delta infections important in Brazil? MF Cicero, NM Pena, LC Santana, R Arnold, RG Azevedo, ÉS Leal, ... BMC infectious diseases 16, 1-10, 2016 | 17 | 2016 |
| Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and São Paulo, Brazil N Mantovani, M Cicero, LC Santana, C Silveira, EP do Carmo, PRF Abrão, ... Virology journal 10, 1-5, 2013 | 17 | 2013 |
| Nitazoxanide superiority to placebo to treat moderate COVID-19–a pilot prove of concept randomized double-blind clinical trial. eClinicalMedicine. 2021; 37: 100981 VF Blum, S Cimerman, JR Hunter, P Tierno, A Lacerda, A Soeiro, ... DOI: https://doi. org/10.1016/j. eclinm, 100981, 2021 | 13 | 2021 |
| Evaluation of GB virus C/hepatitis G viral load among HIV type 1-coinfected patients in São Paulo, Brazil VK Alves-Sousa, SCV Komninakis, GL Baggio-Zappia, AJ Barbosa, ... AIDS research and human retroviruses 28 (10), 1301-1304, 2012 | 13 | 2012 |
| Analysis of transmitted resistance to raltegravir and selective pressure among HIV-1-infected patients on a failing HAART in Sao Paulo, Brazil NP Mantovani, RG Azevedo, JT Rabelato, S Sanabani, RS Diaz, ... Journal of clinical microbiology 50 (6), 2122-2125, 2012 | 8 | 2012 |
| Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II … MV de Almeida Baptista, LT da Silva, S Samer, TM Oshiro, IL Shytaj, ... AIDS research and therapy 19 (1), 2, 2022 | 5 | 2022 |
| 3D Bioprinted Neural‐Like Tissue as a Platform to Study Neurotropism of Mouse‐Adapted SARS‐CoV‐2 BAG de Melo, MV Mundim, RMR Lemes, EM Cruz, TN Ribeiro, ... Advanced Biology 6 (8), 2200002, 2022 | 4 | 2022 |
| Nitazoxanide In Vitro Efficacy Against SARS CoV-2 and In Vivo Superiority to Placebo to Treat Moderate COVID-19 – A Phase 2 Randomized Double-Blind … VF Blum, S Cimerman, JR Hunter, P Tierno, A Lacerda, A Soeiro, ... | 4 | 2021 |
| Identification of a new hepatitis B virus recombinant D2/D3 in the city of São Paulo, Brazil LC Santana, NP Mantovani, MC Ferreira, R Arnold, RLS Duro, ... Archives of virology 162, 457-467, 2017 | 4 | 2017 |
| Latency-associated DNA methylation patterns among HIV-1 infected individuals with distinct disease progression courses or antiretroviral virologic response N Mantovani, A Defelicibus, IT da Silva, MF Cicero, LC Santana, R Arnold, ... Scientific reports 11 (1), 22993, 2021 | 3 | 2021 |
| T Cell-mediated Immune Response and Correlates of Inflammation and their relationship with COVID-19 clinical severity: not an intuitive guess. N Mantovani, L Santana, J Hunter, V Blum, T Vergara, C Gouvea, E Leal, ... | | 2023 |
| 3D Bioprinted Neural‐Like Tissue as a Platform to Study Neurotropism of Mouse‐Adapted SARS‐CoV‐2 (Adv. Biology 8/2022) BAG de Melo, MV Mundim, RMR Lemes, EM Cruz, TN Ribeiro, ... Advanced Biology 6 (8), 2270081, 2022 | | 2022 |
| COVID-19 Clinical Severity, T Cell-Mediated Immune Response, and Correlates of Inflammation: Not an Intuitive Guess NM Pena, LC Santana, JR Hunter, VF Blum, TRC Vergara, JDS Ferraz, ... SPARC Working, COVID-19 Clinical Severity, T Cell-Mediated Immune Response …, 2022 | | 2022 |
| PP 1.44–00107 Longitudinal evaluation of epigenetic age among people living with HIV (PLWH) undergoing multimodal curative interventions M Corley, N Mantovani, L Giron, A Pang, J Galinskas, D Dias, J Hunter, ... | | 2022 |
| Corrigendum to “Nitazoxanide superiority to placebo to treat moderate COVID-19–A Pilot prove of concept randomized double-blind clinical trial.”[EClinicalMedicine 37 (2021) 100981] VF Blum, S Cimerman, JR Hunter, P Tierno, A Lacerda, A Soeiro, ... EClinicalMedicine 41, 2021 | | 2021 |
| Rejeitos radioativos-grupo C ACC López, JS Costa, L Prada, LRM Sá, N Mantovani, R Caravieri, ... Manual de descarte de resíduos da FMVZ-USP, 2017 | | 2017 |
| Resíduos perfurocortantes-grupo E CS Mori, LRM Sá, N Mantovani Manual de descarte de resíduos da FMVZ-USP, 2017 | | 2017 |
| Resíduos químicos-grupo B DA Zanatto, L Prada, LG Mesquita, LRM Sá, LER Raspantini, ... Manual de descarte de resíduos da FMVZ-USP, 2017 | | 2017 |
| Resíduos comuns-grupo D ACC López, LG Mesquita, LRM Sá, LER Raspantini, N Mantovani, ... Manual de descarte de resíduos da FMVZ-USP, 2017 | | 2017 |
